国海证券发布研报称，艾多替尼在NSCLC脑转移患者中头对头击败奥希替尼。第三代EGFR-TKI药物针对脑转移病灶的穿透与抑制能力仍存在短板。艾多替尼是奥希替尼差异化的氘代创新产品，2026年ASCO大会公司公布了艾多替尼在EGFR突变NSCLC脑转移患者一线治疗的ESAONA研究期中分析结果，艾多替尼与奥希替尼iORR为95.5% vs 79.6%，iPFS为NR vs 17.51个月(HR=0.46)，所有预设亚组患者均可从艾多替尼治疗中显著获益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.